Analysts’ Updated EPS Estimates for February, 12th (AVXS, BHF, BMA, BOLD, BRS, BTU, BZH, CDXC, CFMS, CGNT)

Analysts’ updated eps estimates for Monday, February 12th:

Mizuho assumed coverage on shares of AveXis (NASDAQ:AVXS). They issued a buy rating and a $147.00 price target on the stock. The analysts wrote, “We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1.””

Brighthouse Financial (NASDAQ:BHF) had its hold rating reiterated by analysts at Wells Fargo & Co. The firm currently has a $64.00 target price on the stock. The analysts wrote, “We still believe the central issue on the stock is when BHF will reach a variable annuity (VA) asset level equal to CTE95 plus $3 billion, because at that point the company can begin returning capital. The S&P 500 is down for the year (-0.66% YTD) and the increased volatility in equity markets could correspond with increase hedge costs and breakage likelihood but we expect the current variable annuity asset level should still be flat to slightly positive versus the level at year-end 2017 given much higher interest rates (UST 10-year at 2.86% versus 2.43% at the end of December 2017). We expect BHF will update its sensitivity tables versus equity and interest rate in its 10-K filing at the latest. What we liked. 1) Annuity sales were up 32.7% year-over-year and on 26.3% on a linked quarter basis. 2) Variable annuity asset level increased to CTE95 plus $2.6 billion, closer to its goal of CTE95 plus $3.0 billion.””

Banco Macro (NYSE:BMA) was downgraded by analysts at Zacks Investment Research from a buy rating to a strong sell rating. According to Zacks, “Banco Macro Bansud is a leading bank in Argentina. With the most extensive private-sector branch network in the country, Banco Marco provides standard banking products and services to a nationwide customer base. “

Mizuho initiated coverage on shares of Audentes Therapeutics (NASDAQ:BOLD). The firm issued a neutral rating on the stock.

Bristow Group (NYSE:BRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Bristow Group Inc. is a leading provider of helicopter services to the worldwide energy industry. Through its subsidiaries, affiliates and joint ventures, the Company has major transportation operations in the U.S. Gulf of Mexico and the North Sea, and in most of the other major offshore oil and gas producing regions of the world, including Alaska, Australia, Brazil, Mexico, Nigeria, Russia and Trinidad. Additionally, the Company is a leading provider of production management services for oil and gas production facilities in the U.S. Gulf of Mexico. “

Peabody Energy (NYSE:BTU) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Peabody Energy Corporation is a coal company. It provides voice in advocating for sustainable mining, energy access and clean coal technologies. The company serves metallurgical and thermal coal customers primarily in Arizona, Colorado, New Mexico and Wyoming, Illinois, Indiana and Australia. Peabody Energy Corporation is based in St Louis, United States. “

Beazer Homes USA (NYSE:BZH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $17.00 target price on the stock. According to Zacks, “Beazer Homes USA, Inc. designs, builds and sells single family homes. The company designs homes to appeal primarily to entry-level and first move-up home buyers. Their objective is to provide customers with homes that incorporate quality and value. The company’s subsidiary, Beazer Mortgage, originates the mortgages for the company’s home buyers. “

Chromadex (NASDAQ:CDXC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “

ConforMIS (NASDAQ:CFMS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. “

Cogentix Medical (NASDAQ:CGNT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

Columbus McKinnon (NASDAQ:CMCO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Columbus McKinnon, is a broad-line designer, manufacturer and supplier of sophisticated material handling products and integrated material handling solutions that are widely distributed to industrial and consumer markets worldwide. The Company’s material handling products are sold, omestically and internationally, principally to third party distributors and, to a lesser extent, directly to manufacturers and other end-users. The Company’s integrated material handling solutions businesses deal directly with end-users. “

Concert Pharmaceuticals (NASDAQ:CNCE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

CNH Industrial (NYSE:CNHI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CNH Industrial NV designs, produces and sells trucks, commercial vehicles, buses, special vehicles, agricultural and construction equipment, in addition to engines and transmissions for those vehicles and engines for marine application. CNH Industrial NV is based in Amsterdam, the Netherlands. “

Coherent (NASDAQ:COHR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Coherent, Inc. is an American company, designs, manufactures and markets laser systems and components, laser measurement and control products, optics, and laser accessories, which are used both in industry and scientific research. Their markets are the microelectronics industry (e.g., flat panel display manufacturing, integrated circuit packaging, and integrated circuit inspection), scientific research, OEM components, and materials processing (e.g., CO2 lasers for cutting metals). “

Callon Petroleum (NYSE:CPE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Callon Petroleum Company has been engaged in the exploration, development, acquisition and production of oil and gas properties since 1950. “

Camden Property Trust (NYSE:CPT) had its buy rating reissued by analysts at Royal Bank of Canada. The firm currently has a $92.00 price target on the stock.

Carlisle Companies (NYSE:CSL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Carlisle Companies Incorporated is a diversified, global portfolio of niche brands and businesses with highly engineered and high margin products. Carlisle is committed to generating superior shareholder returns by combining a unique management style of decentralization, entrepreneurial spirit, active M&A, and a balanced approach to capital deployment, all with a culture of continuous improvement as embodied in the Carlisle Operating System. Carlisle’s markets include: commercial roofing, agriculture, mining, construction, aerospace, defense, foodservice, healthcare, sanitary maintenance, transportation, industrial, protective coating and auto refinishing. It operates through the following segments: Carlisle Construction Materials, Carlisle Interconnect Technologies, Carlisle Fluid Technologies, Carlisle Brake & Friction, and Carlisle FoodService Products. Carlisle remains committed to the core philosophies of Decentralization, Diversification, Continuous Improvement and an Entrepreneurial Culture. “

HealthStream (NASDAQ:HSTM) had its hold rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $24.00 price target on the stock. The analysts wrote, “On February 12, HSTM announced the sale of its patient experience business to Press Ganey Associates (private) for $65.5 million in cash. The patient experience business represented about 15% of total HSTM revenue.””

Mizuho began coverage on shares of Spark Therapeutics (NASDAQ:ONCE). They issued a buy rating and a $79.00 price target on the stock. The analysts wrote, “We see strong potential for the product in addressing the inherited retinal disease (IRD) market. We are also excited about the hemophilia B program. The company’s hemophilia A program, however, remains to be proven. Recent data was below expectations and we await the anticipated update on the program in 2Q/3Q18 to potentially give greater credit to this indication. We are initiating with a Buy rating and a $79 PT. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these ground-breaking, one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s Luxturna product. FDA approval of Luxturna. In December 2017, Spark’s lead product, Luxturna, gained FDA approval for the treatment of inherited retinal disease.””

Mizuho began coverage on shares of Regenxbio (NASDAQ:RGNX). Mizuho issued a neutral rating and a $28.00 price target on the stock.

TIER REIT (NYSE:TIER) had its buy rating reissued by analysts at BMO Capital Markets. They currently have a $21.00 target price on the stock.

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply